miRNA expression patterns in chemoresistant breast cancer tissues

Biomedicine and Pharmacotherapy

Volumn 68, Issue 8, 2014, Pages 935-942

  Lv, Jianxin ^b   Xia, Kai ^c   Xu, Pengfei ^a   Sun, Erhu ^a   Ma, Jingjing ^a   Gao, Sheng ^a   Zhou, Qian ^a   Zhang, Min ^a   Wang, Fengliang ^a   Chen, Fei ^a   Zhou, Ping ^a   Fu, Ziyi ^a   Xie, Hui ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CLINICAL MEDICAL COLLEGE OF YANGZHOU UNIVERSITY   (China)

^c JIANGYIN PEOPLE S HOSPITAL   (China)

Author keywords

Breast cancer; Chemoresistance; MiRNA

Indexed keywords

DOXORUBICIN; MICRORNA; PROTEIN BINDING;

BIOSYNTHESIS; BREAST NEOPLASMS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MCF 7 CELL LINE; METABOLISM; PHYSIOLOGY;

BREAST NEOPLASMS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; PROTEIN BINDING;

EID: 84916624306     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.09.011     Document Type: Article

References (31)

1. DeSantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014, 64:52-62.
2. Chuthapisith S., Eremin J., El-Sheemey M., Eremin O. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 2010, 19:27-32.
3. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
4. Chen J.Q., Contreras R.G., Wang R., Fernandez S.V., Shoshani L., Russo I.H., et al. Sodium/potassium atpase (na+, k+-atpase) and ouabain/related cardiac glycosides: a new paradigm for development of anti- breast cancer drugs?. Breast Cancer Res Treat 2006, 96:1-15.
5. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and micrornas. Drug Resist Updat 2007, 10:59-67.
6. Ng E.K., Wong C.L., Ma E.S., Kwong A. Micrornas as new players for diagnosis, prognosis, and therapeutic targets in breast cancer. J Oncol 2009, 2009:305420.
7. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microrna genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
8. Chen G.Q., Zhao Z.W., Zhou H.Y., Liu Y.J., Yang H.J. Systematic analysis of microrna involved in resistance of the mcf-7 human breast cancer cell to doxorubicin. Med Oncol 2010, 27:406-415.
9. Krol J., Loedige I., Filipowicz W. The widespread regulation of microrna biogenesis, function and decay. Nat Rev Genet 2010, 11:597-610.
10. Liang Z., Wu H., Xia J., Li Y., Zhang Y., Huang K., et al. Involvement of mir-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010, 79:817-824.
11. Koch M., Krieger M.L., Stolting D., Brenner N., Beier M., Jaehde U., et al. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling. Biochem Pharmacol 2013, 85:1077-1090.
12. Kastl L., Brown I., Schofield A.C. Mirna-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 2012, 131:445-454.
13. Pogribny I.P., Filkowski J.N., Tryndyak V.P., Golubov A., Shpyleva S.I., Kovalchuk O. Alterations of micrornas and their targets are associated with acquired resistance of mcf-7 breast cancer cells to cisplatin. Int J Cancer 2010, 127:1785-1794.
14. Chen J., Tian W., Cai H., He H., Deng Y. Down-regulation of microrna-200c is associated with drug resistance in human breast cancer. Med Oncol 2012, 29:2527-2534.
15. Ying W., Wang S., Shi J., Sun Y. Er-/er+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection. Med Oncol 2012, 29:495-502.
16. Galea M.H., Blamey R.W., Elston C.E., Ellis I.O. The nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
17. Jiang X., Xue M., Fu Z., Ji C., Guo X., Zhu L., et al. Insight into the Effects of Adipose Tissue Inflammation Factors on miR-378 Expression and the Underlying Mechanism. Cell Physiol Biochem 2014, 33(6):1778-1788.
18. Qian B., Katsaros D., Lu L., Preti M., Durando A., Arisio R., et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 2009, 117(1):131-140.
19. Bao L., Haque A., Jackson K., Hazari S., Moroz K., Jetly R., et al. Increased expression of p-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4t1 breast cancer model. Am J Pathol 2011, 178:838-852.
20. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., et al. Retraction: genomic signatures to guide the use of chemotherapeutics. Nat Med 2011, 17:135.
21. Hu M., Xia M., Chen X., Lin Z., Xu Y., Ma Y., et al. Microrna-141 regulates smad interacting protein 1 (sip1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci 2010, 55:2365-2372.
22. Neves R., Scheel C., Weinhold S., Honisch E., Iwaniuk K.M., Trompeter H.I., et al. Role of DNA methylation in mir-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes 2010, 3:219.
23. van Jaarsveld M.T., Helleman J., Boersma A.W., van Kuijk P.F., van Ijcken W.F., Despierre E., et al. Mir-141 regulates keap1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013, 32:4284-4293.
24. Bhatnagar N., Li X., Padi S.K., Zhang Q., Tang M.S., Guo B. Downregulation of mir-205 and mir-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010, 1:e105.
25. Mitamura T., Watari H., Wang L., Kanno H., Hassan M.K., Miyazaki M., et al. Downregulation of mirna-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase met. Oncogenesis 2013, 2:e40.
26. Laurila E.M., Kallioniemi A. The diverse role of mir-31 in regulating cancer associated phenotypes. Genes Chromosomes Cancer 2013, 52:1103-1113.
27. Reinhart B.J., Slack F.J., Basson M., Pasquinelli A.E., Bettinger J.C., Rougvie A.E., et al. The 21-nucleotide let-7 rna regulates developmental timing in caenorhabditis elegans. Nature 2000, 403:901-906.
28. Boyerinas B., Park S.M., Hau A., Murmann A.E., Peter M.E. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010, 17:F19-F36.
29. Mitra D., Das P.M., Huynh F.C., Jones F.E. Jumonji/arid1 b (jarid1b) protein promotes breast tumor cell cycle progression through epigenetic repression of microrna let-7e. J Biol Chem 2011, 286:40531-40535.
30. Wang Q., Huang Z., Ni S., Xiao X., Xu Q., Wang L., et al. Plasma mir-601 and mir-760 are novel biomarkers for the early detection of colorectal cancer. PLoS ONE 2012, 7:e44398.
31. Kim S.Y., Lee Y.H., Bae Y.S. Mir-186, mir-216b, mir-337-3p, and mir-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase ckii in human colorectal cancer cells. Biochem Biophys Res Commun 2012, 429:173-179.